Intranasal Corticosteroids Market Analysis

The global intranasal corticosteroids market is segmented and analyzed for demand and supply by administration into aerosol liquid, spray, and implants, out of which, the spray segment is anticipated to hold the notable share in the global intranasal corticosteroids market during the forecast period on account of the flexible administration and convenient affordability. It is directly applied or sprayed into the nasal passage to reduce inflammation in conditions such as cold and fever. According to American Lung Fever Association, around 200 types of viruses are responsible to cause colds and other minor infections. Additionally, an individual can get 2 to 4 colds per year. Furthermore, intranasal corticosteroids are highly available in spray form.

Our in-depth analysis of the global market includes the following segments:

By Drugs Type	Prescribed drugs Budesonide Ciclesonide Others
By Rhinitis Type	Non - Allergic Perennial Allergic Seasonal Allergic Rhinitis
By Adminstartion	Aerosol Liquid Spray Implantes
By Distribution Channel	Retails & Hospitals Pharmiced Drugs Store Online

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of intranasal corticosteroids is estimated at USD 7.44 billion.

Intranasal Corticosteroids Market size was valued at USD 7.13 billion in 2024 and is likely to cross USD 13.61 billion by 2037, registering more than 5.1% CAGR during the forecast period i.e., between 2025-2037.

Asia Pacific industry is predicted to account for largest revenue share by 2037, on account of higher prevalence of type 1 diabetes, rheumatoid arthritis, and other types of sclerosis.

The major players in the market are AstraZeneca PLC, Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., GSK plc, Sanofi S.A., Ivax Pharmaceuticals, Inc., OptiNose US, Inc., Chattem Chemicals, Inc., and Intersect ENT Inc.

Intranasal Corticosteroids Market Analysis